secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0000950170-24-038902
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen reports Phase 1a SZN-043 data: safe, target engagement, liver function effects; Phase 1b starts
--------------------------------------------------------------------------------

- Phase 1a enrolled 48 subjects (40 healthy, 8 cirrhotic); doses 0.5-3 mg/kg IV; no serious adverse events.
- Demonstrated target engagement via transient ALP increases and Wnt pathway activation by methacetin breath test.
- In cirrhotic patients, dose-dependent pharmacodynamic effect and improvement in liver function via HepQuant test observed.
- Initiating Phase 1b proof-of-concept trial in severe alcohol-associated hepatitis; data expected first half 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017024038902/0000950170-24-038902-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017024038902/srzn-20240401.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-038902

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer